58
Participants
Start Date
October 31, 2014
Primary Completion Date
August 1, 2018
Study Completion Date
August 31, 2018
recombinant human thrombopoietin
Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
Institute of Hematology & Blood Diseases Hospital, Tianjin
Institute of Hematology & Blood Diseases Hospital, China
OTHER